Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaya HoldingsKAYS -66.67% EV-to-EBITDA is 0.15 as of Aug. 11, 2026. The stock has 4 warning signs investors should review. Among 736 Drug Manufacturers companies, Kaya Holdings ranks better than 98.23% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kaya Holdings's enterprise value is $-1.55 Mil.
Kaya Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 was $-10.54 Mil. Therefore, Kaya Holdings's EV-to-EBITDA for today is 0.15.
The historical rank and industry rank for Kaya Holdings's EV-to-EBITDA or its related term are showing as below:
KAYS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -51.77 Med: -1.38 Max: 15.26
Current: 0.15
During the past 12 years, the highest EV-to-EBITDA of Kaya Holdings was 15.26. The lowest was -51.77. And the median was -1.38.
KAYS's EV-to-EBITDA is ranked better than 98.23% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.185
vs KAYS: 0.15
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Kaya Holdings (OTCPK:KAYS) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kaya Holdings's PE Ratio (TTM) for today is calculated as:
Kaya Holdings's share price for today is $0.0001.
Kaya Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.135.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Kaya Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Kaya Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kaya Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kaya Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Kaya Holdings's EV-to-EBITDA falls into.
Kaya Holdings's current Enterprise Value is $-1.55 Mil.
Kaya Holdings's EBITDA for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.54 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaya Holdings (KAYS) has a EV-to-EBITDA of 0.15 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kaya Holdings. According to the industry distribution chart, Kaya Holdings ranks #13 out of 736 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Kaya Holdings' EV-to-EBITDA too high?
Kaya Holdings' current EV-to-EBITDA is 0.15. The Drug Manufacturers industry median EV-to-EBITDA is 13.19. Kaya Holdings' value of 0.15 is 98.9% below this industry median. Based on the distribution chart, Kaya Holdings ranks #13 out of 736 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Kaya Holdings' EV-to-EBITDA compare to STEK and KOAN?
According to the Drug Manufacturers industry distribution chart, Kaya Holdings ranks #13 out of 736 companies for EV-to-EBITDA. This places Kaya Holdings in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 13.19. Kaya Holdings' value of 0.15 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.19, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kaya Holdings's current EV-to-EBITDA of 0.15 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Kaya Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaya Holdings's current EV-to-EBITDA is 0.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaya Holdings stock overvalued right now?
Kaya Holdings (KAYS) has a current EV-to-EBITDA of 0.15. The current EV-to-EBITDA is 0.15 and 98.9% below the Drug Manufacturers industry median of 13.19. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Kaya Holdings (KAYS), the current EV-to-EBITDA is 0.15 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kaya Holdings Inc is a holding company. It is focusing on wellness and mental health through operations in psychedelic treatment clinics, medical and recreational cannabis, and CBD products. The company own and operate a medical cannabis dispensary in the United States. Its has produced, distributed, and/or sold a full range of premium cannabis products including flower, oils, vape cartridges and cannabis infused confections, baked goods and beverages through a fully integrated group of subsidiaries and companies supporting distinctive brands.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAYS has been successfully added to your 
